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Background: Little data is available on the real-world socio-economic burden and outcomes in schizophrenia. This
study aimed to assess persistence, compliance, costs and Health-Related Quality-of-Life (HRQoL) in young patients
undergoing antipsychotic treatment according to clinical practice.
Methods: A naturalistic, longitudinal, multicentre cohort study was conducted: we involved 637 patients aged
18–40 years, with schizophrenia or schizophreniform disorder diagnosed ≤10 years before, enrolled in 86 Italian
Mental Health Centres and followed-up for 1 year. Comparisons were conducted between naïve (i.e., patients
visiting the centre for the first time and starting a new treatment regimen) and non naïve patients.
Results: At enrolment, 84% of patients were taking atypical drugs, 3.7% typical, 10% a combination of the two classes,
and 2% were untreated. During follow-up, 23% of patients switched at least once to a different class of treatment, a
combination or no treatment. The mean Drug-Attitude-Inventory score was 43.4, with 94.3% of the patients considered
compliant by the clinicians. On average, medical costs at baseline were 390.93€/patient-month, mostly for drug treatment
(29.5%), psychotherapy (29.2%), and hospitalizations (27.1%). Patients and caregivers lost 3.5 days/patient-month of
productivity. During follow-up, attitude toward treatment remained fairly similar, medical costs were generally stable,
while productivity, clinical statusand HRQoL significantly improved. While no significantly different overall direct costs
trends were found between naïve and non naïve patients, naïve patients showed generally a significant mean higher
improvement of clinical outcomes, HRQoL and indirect costs, compared to the others.
Conclusions: Our results suggest how tailoring the treatment strategy according to the complex and specific patient
needs make it possible to achieve benefits and to allocate more efficiently resources. This study can also provide
information on the most relevant items to be considered when conducting cost-effectiveness studies comparing specific
alternatives for the treatment of target patients.
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According to the World Health Organization, there
are 24 million people suffering from schizophrenia
worldwide, with an average prevalence of around 7 per
1000 adults, mostly in the age group 15–35 years [1].
Schizophrenia is a chronic condition characterized by
an early onset, usually during adolescence, severe* Correspondence: mantovani@unina.it
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reproduction in any medium, provided the orsymptomatology and chronic course [2]. This disease
is included among the top ten causes worldwide of
long-term and devastating disability, with wide-
ranging and long-lasting impact for people suffering
from the illness, their families and society as a whole
[2-6]. Patients’ clinical condition and wellbeing deteri-
orate during the course of the disease, with enormous
repercussions on their ability to perform daily activ-
ities, to work, to have an effective family and social
life, and hence on their wellbeing [4-6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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different cost items attributable to schizophrenia and its
management [6-12]. According to a systematic review of
cost of illness studies conducted in the US and several
European countries, schizophrenia involves a high mag-
nitude of burden to patients, their families and society:
the expenditure for schizophrenia ranges from 1.5 to
3.0% of annual healthcare budget in developed countries
[6,10]. Generally, one to two thirds of the total health
care cost is related to hospitalizations [7,10-12]. For in-
stance, in the US it has been estimated that schizo-
phrenic patients occupy about 25% of all psychiatric
hospital beds, and 40% of all days staying in these hospi-
tals is for schizophrenia-related reasons [11]. In the UK,
the use of hospital inpatient care by people with schizo-
phrenia is substantial: in 2006–2007, 34,407 admissions
were reported for schizophrenia and related disorders in
England, resulting in 2,232,724 inpatient bed days. This
amounted to 16% of all admissions and 34% of all bed
days related to psychiatric inpatient care [12]. Among
the total direct costs, hospitalizations can account for up
to 94% [6], while drugs generate lower costs (between 2
and 13%) [6,13,14]. A considerable contribution to the
cost to society comes from the indirect costs (i.e., prod-
uctivity losses), because of employment difficulties, high
early mortality rate and patients’ families loss of prod-
uctivity. According to some authors, schizophrenia-
related indirect costs account for approximately half of
the total cost of illness [6,9,10,13-15]. In the United
Kingdom, it has been estimated that indirect costs are
four times higher than direct costs [16]. Other signifi-
cant cost items have also been identified, like those in-
volving the criminal justice system and related to the
impairment of wellbeing (intangible costs), although
these costs are difficult to estimate [6].
Some research has shown that compliance to treat-
ment is associated with improvement in Health Re-
lated Quality of Life (HRQoL) [17,18] and clinical
outcomes [19-21]. Other studies show that outcomes
in patients with a first-episode psychosis may be im-
proved by early intervention treatment and reduction
of the untreated period [22-27], but long term effects
are still not clear [26-28].
Despite the several studies available on some as-
pects related to the burden of disease, a complete pic-
ture of the real-world societal costs and treatment
outcomes is still lacking, especially on young schizo-
phrenia patients.
The aim of this study was to assess compliance and at-
titude toward antipsychotic drug treatment, persistence,
clinical status and HRQoL, and to estimate health care
costs and loss of productivity in young adult patients di-
agnosed with schizophrenia or schizophreniform dis-
order, who needed long term antipsychotic treatment.Methods
Subjects and procedures
We conducted a naturalistic, longitudinal, ambispective
(i.e., both retrospective and prospective) multicentre co-
hort study, named COMETA (COMpliance, costi e
qualità della vita. Esperienze cliniche nella Terapia con
Antipsicotici).
Patients were consecutively enrolled during 2006 and
2007 in 86 Mental Health Centres throughout Italy. To be
considered eligible, patients had to satisfy the following in-
clusion criteria: age from 18 to 40 years, diagnosis of
Schizophrenia or Schizophreniform disorder according to
the DSM-IV criteria [29], illness duration of 10 years or less
before study entry, necessity of long term antipsychotic
treatment. At enrolment, the patients had to be in treat-
ment with oral antipsychotic drugs, either started previ-
ously or started at the time of enrolment. Among the
eligible patients, if they were visiting the centre for the first
time and starting a new treatment regimen (i.e., starting a
new drug or a new dosage), these patients were classified
as “naïve”.
Patients were not eligible if they had concomitant diseases
for which there was life expectancy of less than 52 weeks, if
at the time of enrolment they were hospitalized or staying in
Residential Care Units, if they were attending a specialist
centre for the care and treatment of people addicted to
drugs or alcohol, or if they were pregnant or breast-feeding.
At the enrolment examination, patients’ data attributable
to the previous 90 days were collected (retrospective
period) and they were then targeted to be followed up for
up to 12 months (prospective period). During the prospect-
ive follow-up, data collection occurred at 12 ± 2 (follow-up
examination 1), 36 ± 2 (follow-up examination 2), 52 ± 2
(follow-up examination 3) weeks: a 2-week time variation
per examination was allowed in order to make the occur-
rence of examinations coincident with those established
according to clinical practice.
The study was performed in accordance with the guide-
lines of the International Conference on Harmonization
for Good Clinical Practice as stipulated in the Declaration
of Helsinki [30]. Local Ethics Committees approval was
obtained at each of the participating study sites. To par-
ticipate, each patient had to sign an informed consent
form.
Assessments
In order to achieve good quality of the data collected
and a good level of inter-rater reliability, the centres par-
ticipated in two kick-off meetings before the study
started, within a 3-years long educational program in
which the raters (clinical investigators) who collected the
data and assisted the patients during data collection
were trained for the completion of all the instruments
used in the project.
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tus, HRQoL, drug treatment, compliance and attitude to-
ward antipsychotic treatment, use of health care resources,
and loss of productivity were collected by means of case re-
port forms, scales/questionnaires completed by the phys-
ician (socio-demographic and clinical data, costs, opinion
on patients’ compliance) or by the patient (HRQoL and at-
titude toward antipsychotic treatment).
Socio-demographic data included patients’ gender and
age, education, family and working status, and receipt of
economic support for their condition.
Clinical data were based on diagnosis (schizophrenia
vs. schizophreniform disorder), disease severity, type of
schizophrenia, duration of disease, age at onset of symp-
toms, first treatment, first hospitalization, psychiatric symp-
toms. Functioning and disease severity were assessed using
the Positive And Negative Syndrome Scale (PANSS), the
Clinical Global Impression – Severity (CGI-S) and the Glo-
bal Assessment of Functioning (GAF) scales. PANSS is a
30-item scale measuring the presence of positive and nega-
tive syndromes in schizophrenia patients and the severity
of psychopathology in the week before the day of assess-
ment. Higher scores indicate more severe psychopathology
[31,32]. CGI-S assesses clinical symptom severity in the
week before the day of assessment, with a score ranging
from 1 (not ill) to 7 (among the most severely ill patients)
[29,33,34]. With the GAF scale we measured the overall
level of symptomatology and social functioning during the
previous 3 months, on a scale from 0 to 100, with higher
values indicating higher levels of functioning [29,35].
In order to assess their HRQoL, patients completed
the EQ-5D [36] and the SF-36 (Short-Form 36-item
Health Survey) [37]. These questionnaires were chosen
for their ability to evaluate both the physical and psycho-
logical component of HRQoL and both have proved to
be suitable for self-administration in patients with
schizophrenia [38-41]. With EQ-5D, the respondents are
asked about their HRQoL on the current day. It consists
of two main parts: the first part generates a health pro-
file (EQ-5D profile) consisting of 5 domains, namely
“mobility”, “self care”, “anxiety or depression”, “usual ac-
tivities” and “pain or discomfort”, each with three levels
of severity (“no problem”, “some/moderate problems”,
“extreme problems/impossible to do”). The second part
of the questionnaire consists of a visual analogue scale
(EQ-5D VAS), measuring overall HRQoL ranging from 0
(worst imaginable health state) to 100 (best imaginable
health state). Results from the EQ-5D descriptive system
were converted into a utility score by means of an algo-
rithm that uses population-based (social) values. Because
specific conversion values for the Italian population are
not yet available, we used social values from the United
Kingdom in order to convert our EQ-5D descriptive sys-
tem results to the EQ-5D utility index [42].SF-36 assesses HRQoL in eight dimensions related to
the physical and mental components of health. It is pos-
sible to synthesize the information obtained with the
eight domains into two summary scores, one specific for
physical health (Physical Summary Score - PCS)and the
other for mental health (Mental Summary Score -
MCS): the higher the score, the better the component of
HRQoL measured [37,43]. For this study, PCS and MCS
results will be shown.
Data on both antipsychotic and concomitant drug treat-
ments were taken, recording information on type of drug,
dosing, duration of treatment and details on switches or
interruptions.
Compliance and attitude toward antipsychotic treat-
ment at the time of each examination were assessed with
the 30-item version of Drug Attitude Inventory (DAI-30)
[44], a scale self-completed by the patients to measure
their subjective response to medication as well as their
attitude towards pharmacological treatment, illness and
health. We computed the score on 25 items which,
according to recent research, mostly contribute to in-
crease the score’s internal consistency [45]: accordingly,
the score ranges from a minimum of 25 (negative attitude)
to a maximum of 50 (the higher the score, the more posi-
tive the attitude). Patients’ compliance was also assessed
according to the physicians’ opinion: these were asked to
specify whether the patient took the antipsychotic treat-
ment according to prescription, with 6 possible answers:
always (81-100% of times), frequently (61-80% of times),
sometimes (41-60% of times), very rarely (21-40% of
times), never (≤20% of times), or not applicable if it was
the first time for the physician to see that patient.
Persistence with antipsychotic treatment was assessed
by calculating the number of days the patients were in
either atypical or typical class treatment until interrup-
tion or switch to an alternative class of drugs. We also
calculated the proportion of patients who switched at
least once, during the follow up period, and the number
of switches occurring among the atypical, typical, com-
bined regimen (any typical or atypical), or no treatment.
Finally, we calculated the occurrence of relapse, identi-
fied in terms of admittance to hospital or residential care
units during the follow up period.
Direct and indirect costs
Direct costs were assessed with the information obtained
from the physician on the following medical resource
consumption: pharmacological treatment with antipsy-
chotics, concomitant drug treatment, psychotherapy,
hospital admissions in both full-day and/or day-hospital,
admissions in residential care units, nurse home visits,
specialist medical examinations, laboratory and instru-
mental tests. Direct costs were quantified in mone-
tary terms by multiplying the amount of the resource
Cortesi et al. BMC Psychiatry 2013, 13:98 Page 4 of 16
http://www.biomedcentral.com/1471-244X/13/98consumed by the corresponding unit cost, according to
prices and tariffs applied in Italy in 2007. Both the pa-
tients’ and the National Health Service (NHS) perspec-
tives were adopted to estimate these costs, according to
the actual payer. For costs paid by the NHS, pharmaco-
logical treatment unit costs were obtained from the Ital-
ian Drug Agency price list [46]. Costs of hospital
admissions were calculated according to the Diagnosis
Related Group (DRG) regional tariffs [47]. Costs for nurse
home visits, diagnostic tests, medical specialist examina-
tions and psychotherapy were obtained from the regional
outpatient lists [48]. Finally, a specific tariff was used to
assign costs for access to residential care units, structured
psychosocial rehabilitation groups or day centres [49]. If
patient out-of-pocket costs were incurred, the information
reported by patients was used. However, the NHS in Italy
is responsible for providing and paying for most of the
health care costs to manage individuals with chronic con-
ditions (schizophrenia), hence we did not expect to esti-
mate high costs paid by the patients for these costs.
Indirect costs were estimated by calculating patients’ and
their caregivers’ loss of productivity for reasons attributable
to the target condition. The estimate of loss of productivity
is not easy to perform in this population: some patients
were still students, while others did not complete even
their compulsory education, probably for reasons related
to their condition, which must be considered as a loss of
productivity and possible cause of future loss. Other pa-
tients were performing unpaid work, like an intern or ap-
prenticeship, obtained because of and according to their
condition. In order to avoid a biased monetary estimate of
productivity loss based on national working tariffs and
standard methods (e.g. human capital approach [50]),
which do not take into account the cost attributable to the
loss of the opportunity to study and/or work due to the ill-
ness, we preferred not to assign a monetary value but ra-
ther to assess this component of cost of illness according
to the following method. First – the frequency of idle pa-
tients was estimated: according to their age ranging from
18 to 40 years, all the patients were expected to be stu-
dents, involved in paid or unpaid job, or at least house-
wives. If they were not doing any of these activities, they
were classified as idle for reasons attributable to their clin-
ical condition. Second - regardless of their working status,
patients were also asked if they lost days of work, school or
in doing any usual activity (e.g. housekeeping) for reasons
attributable to their condition. Loss of productivity was es-
timated also for the patients’ caregivers: information on
their job and on the number of days they lost from work/
study/usual activities was collected.
Statistical analyses
The sample socio-demographic, clinical and HRQoL
characteristics were described using proportions forcategorical data, mean and/or median as central ten-
dency parameters for continuous data, standard devi-
ation (SD), minimum (min) and maximum (max) values
as dispersion parameters. The persistence with the anti-
psychotic drug treatment was estimated by means of
Kaplan-Meier curves, by comparing the mean number
of patient-days (i.e. number of days each patient
persisted in each treatment) of permanence in the same
drug class (i.e. class of atypical, typical, combination of
both classes, or no antipsychotic drug).
Relapse was calculated as the proportion of patients
with at least one relapse event during follow up and as
the mean and SD number of patient-days free from
relapse.
Consumption of health care resources is expressed as
the proportion of patients consuming each health care
item, and as mean (min-max) number of examinations,
days, sessions per patient-month. Monetary values are
reported as mean €/patient-month. Indirect costs are
reported in terms of proportions of idle patients, of pa-
tients and caregivers losing at least 1 day of productivity,
and as mean (min-max) days/patient-month or days/
caregiver-month of productivity lost. The use of mean
days per patient-month makes it possible to adjust the
results for the different periods of time between the ex-
aminations when the data were collected. Because of the
highly skewed distribution of cost variables, we report
the distribution of both costs and days of productivity
lost per patient per month as a variability measure.
Data collected at each examination (at enrolment, and
12 ± 2, 36 ± 2 and 52 ± 2 weeks later) were analysed and
reported to show the trend found during the observa-
tional period. To compute the means of the variables,
the number of patients (when assessing e.g. clinical sta-
tus, HRQoL, compliance, rate of idle patients) or the
number of patient-months (in the assessment of costs
occurring during the reference period) available at each
examination were used as denominators.
Comparisons between naïve and non naïve patients
were conducted. To compare baseline characteristics,
between-group testing was performed with independent
sample t-tests for continuous variables and Chi-square
tests or Fischer exact tests for categorical variables.
Two-way repeated measures ANOVA (with time set as
repeated factor) was used to assess the trend of the mea-
surements during the observational period on the full
sample and to compare the trends between naïve and
non-naïve patients. A Greenhouse-Geisser correction
was applied if the assumption of sphericity was not res-
pected. If the trend was statistically significant (p < 0.05),
multiple comparisons using the Bonferroni correction
were performed to assess the differences between each
pair of examinations. All analyses were performed using
SPSS version 18.0 software (SPSS, Chicago, IL).
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Sample description
A total of 661 patients were enrolled in 86 Mental
Health centres scattered all over Italy, during 2006 and
2007: 24 patients were identified to be not eligible for
participation in the study, so the valid study sample in-
cluded 637 patients at baseline.
Among the valid patients, at enrolment, 90 (14.1%)
were visiting the centre for the first time, while 124
(19.5) were in need of a treatment change or initiation
(12 out of the 124 patients had not taken any treatment
in the previous 90 days). Overall, 63 patients (9.9%) were
identified as naïve, as they were both visiting the centre
for the first time and starting a new treatment regimen.Table 1 Patients’ socio-demographic characteristics at enrolm
Description Values
Gender:
Males, n (%) 414 (65.0)
Age (years):
Median (min-max) 31.0 (18–40)
Mean (SD) 30.9 (5.49)
Body Mass Index:
Mean (SD) 27.2 (5.3)
Education:
Primary school, n (%) 27 (4.2)
Lower secondary school, n (%) 301 (47.3)
Upper secondary school, n (%) 271 (42.5)
Graduate/post-graduate, n (%) 38 (6.0)
Marital status:
Single, n (%) 546 (85.7)
Married, n (%) 66 (10.3)
Divorced/separated, n (%) 24 (3.8)
Widow, n (%) 1 (0.2)
Family and caregiver:
Patients living alone, n (%) 28 (4.4)
Patients with a caregiver, n (%) 309 (48.5)
Working status:
Idle, n (%) 336 (52.8)
Working$, n (%) 225 (35.3)
Student, n (%) 60 (9.4)
Housewife, n (%) 16 (2.5)
Economic support for schizophrenic condition:
Disability pension, n (%) 187 (29.4)
Sickness benefit, n (%) 7 (1.1)
Both, n (%) 5 (0.8)
* A Chi-square test was applied.
** A Fisher’s exact test was applied.
‡ An independent sample Student’s t-test was applied.
$The term “working”refers to subjects with paid work and unpaid work (e.g., internTables 1 and 2 show the description of the full sample
characteristics at baseline, and also report differences be-
tween naïve and non naïve patients.
Fifty patients, 7.8% of the study sample, were not ob-
served until the end of the study for various reasons:
614 came back for the first follow-up examination, 603
underwent the second follow-up examination, and 587
patients were observed for the full observational period.
As regards the reason for discontinuation, 39 patients
(6.1%) asked their clinician to withdraw from the study,
while 5 had reasons not allowing them to remain in the
study (pregnancy, death, severe adverse event), 5 (0.8%)
moved to a different city (3) or different care centre (2),
and 1 patient was lost to follow-up. There were noent (N = 637)
Non naïve (N = 574) Naïve (N = 63) p-value
374 (65.2) 40 (63.5) 0.793*
32.0 (18–40) 28.0 (18–40) <0.0001‡
31.2 (5.4) 28.3 (5.9)
27.4 (5.4) 25.2 (4.3) 0.002‡
25 (4.4) 2 (3.2) 0.164**
277 (48.3) 24 (38.1)
240 (41.8) 31 (49.2)
32 (5.6) 6 (9.5)
494 (86.1) 52 (82.5) 0.576**
57 (9.9) 9 (14.3)
22 (3.8) 2 (3.2)
1 (0.2) 0
25 (4.4) 3 (4.8) 0.751**
299 (52.1) 29 (46.0) 0.619*
313 (54.5) 24 (38.1) 0.100**
200 (34.8) 24 (38.1)
48 (8.4) 12 (19.0)
13 (2.3) 3 (4.8)
185 (32.2) 2 (3.2) <0.0001**
7 (1.2) 0
5 (0.9) 0
, apprenticeship).
Table 2 Patients’ clinical characteristics and HRQoL at enrolment (N = 637)
Description Values Non naïve (N = 574) Naïve (N = 63) p-value
Diagnosis:
Schizophrenia, n (%) 549 (86.2) 510 (88.9) 39 (61.9) <0.0001*
Schizophreniform disorder, n (%) 88 (13.8) 64 (11.1) 24 (38.1)
Type of schizophrenia:
Catatonic, n (%) 7 (1.3) 7 (1.4) 0 0.661**
Disorganized, n (%) 56 (8.8) 51 (10.0) 5 (12.8)
Paranoid, n (%) 372 (67.8) 345 (67.6) 27 (69.2)
Undifferentiated, n (%) 88 (16.0) 81 (15.9) 7 (17.9)
Residual, n (%) 26 (4.1) 26 (5.1) 0
Duration of illness(years):
Mean (SD) 3.7 (3.0) 4.0 (3.0) 1.2 (2.5) <0.0001‡
Diagnosis:
<1 year before, n (%) 175 (27.5) 128 (22.3) 48 (76.2) <0.0001*
1–5.99 years before, n (%) 284 (44.6) 273 (47.6) 9 (14.3)
6–10 years before, n (%) 178 (27.9) 173 (30.1) 6 (9.5)
Age at onset of psychotic symptoms(years):
Mean (SD) 24.2 (5.5) 24.1 (5.5) 24.6 (5.9) 0.576‡
Age at first antipsychotic treatment(years):
Mean (SD) 25.5 (5.4) 25.5 (5.3) 26.1 (6.0) 0.370‡
Age at first hospitalization(years):
Mean (SD) 26.2 (5.4) 26.2 (5.4) 25.5 (5.8) 0.589‡
PANSS score
Positive subscale, Mean (SD) 17.3 (7.4) 16.9 (7.2) 21.6 (7.9) <0.0001‡
Negative subscale, Mean (SD) 23.7 (8.5) 23.5 (8.5) 25.7 (8.3) 0.050‡
General subscale, Mean (SD) 45.6 (14.6) 44.8 (14.6) 52.7 (13.5) <0.0001‡
Total, Mean (SD) 86.6 (27.4) 85.2 (27.1) 100.0 (26.2) <0.0001‡
GAF score:
Mean (SD) 54.1 (13.8) 54.6 (13.9) 49.6 (12.6) 0.007‡
CGI-S score:
Mean (SD) 4.3 (2.2) 4.3 (1.1) 4.6 (0.9) 0.011‡
EQ-5D VAS
Mean (SD) 63.5 (17.9) 63.5 (17.9) 63.5 (18.2) 0.991‡
EQ-5D utility score
Mean (SD) 0.71 (0.3) 0.70 (0.3) 0.72 (0.3) 0.656‡
SF-36 PCS
Mean (SD) 47.5 (9.3) 47.5 (9.4) 47.4 (9.2) 0.928‡
SF-36 MCS
Mean (SD) 39.0 (9.6) 39.3 (9.5) 36.6 (10.4) 0.049‡
* A Chi-square test was applied.
** A Fisher’s exact test was applied.
‡ An independent sample Student’s t-test was applied.
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the follow-up and those who discontinued in socio-
demographic aspects, clinical characteristics and HRQoL.
According to these data, we do not have elements to sus-
pect that discontinuations were related to patients’ out-
comes and that could have biased our results.
Overall, the patients were observed for a mean of 14.4
(3.0-17.9) months, considering both the retrospective
and prospective period.
During follow up, 109 patients, 17.1% of the study
sample had symptom relapses. On average, 460.2 (SD =
5.7) days/patient free from symptom relapse were esti-
mated through the full observational period.
Drug treatment
Patients were treated with several different antipsychotics
(18 drugs in total) and concomitant therapies. Concomi-
tant therapy mostly consisted of anxiolytics, used by ap-
proximately 40% of the patients, antidepressants, used by
30%, anticholinergics, used by 11%, and antiepileptic med-
ications, used by 14% of the patients over the observa-
tional period. As regards antipsychotic drugs, during both
the 90 days before enrolment and the prospective follow
up period, one third of the study sample took olanzapine
and one third risperidone; the other most frequently used
drugs were haloperidol, aripiprazole, quetiapine and cloza-
pine (Figure 1).
At enrolment, the patients reported a mean DAI score
of 43.4, with a minimum of 25 (1 patient, 0.2%) and a
maximum of 50 (45 patients, 7.1%). With the exclusion
of 90 patients, for whom this information was not avail-
able at enrolment as they were attending the centre for
the first time, the physicians reported that 71.1% (out ofFigure 1 Antipsychotic drug treatment during the 90 days before enr
to the patients taking the drug at least once during the 90 days before en
period (light grey bars), either alone or with other antipsychotic drugs. Perc547 patients) always took the prescribed antipsychotic
therapy, 23.2% took it very frequently, while 4.0% took
the therapy sometimes, 1.3% very rarely and 0.4% never
took the prescribed therapy.
During the 90 days before enrolment, 58.6% of the 637
patients took only atypical antipsychotics, 2.8% only typ-
ical antipsychotics, 6.0% a combination of both atypical
and typical, and 1.7% never started an antipsychotic
treatment. In that period, 30.9% of the study sample
switched at least once to an atypical, typical, combin-
ation or no antipsychotic treatment.
Antipsychotic drug treatment used after the enrolment
examination included atypical drugs, started in 84% of
the patients. During follow-up 13.4% of these patients
switched to typical, combined or no treatment (Figure 2).
Overall, 22.9% of the study sample switched their treat-
ment (class of drugs) at least once, 11% switched at least
twice, while 1.3% switched 4 or 5 times.
During follow-up, the persistence with atypical antipsy-
chotics was higher than the persistence with typical anti-
psychotic therapy (Figure 3): on average, 402.8 patient-days
were estimated for atypical antipsychotic treatment, and
263.0 patient-days for typical treatment.
Other health care resource consumption
Table 3 shows details on the proportion of patients and
amount of other health care resources consumed during
the observational period. Overall, 24% of the patients re-
ceived psychotherapy before enrolment, for an overall
mean of 1.7 days/patient-month, with a decreasing trend
recorded during the follow-up period.
One criterion of eligibility was not staying at residen-
tial care units at the time of enrolment: however, 1.7% ofolment and during prospective follow up period. Percentages refer
rolment (dark grey bars) and/or during the prospective follow up
entages reported do not necessarily sum up to 100%.
Figure 2 Antipsychotic drug treatment and switches taken from enrolment during the follow up period. Each box reports the percentage
of patients taking one out of the four treatment options (typical, atypical, combination of typical and atypical, none). Vertical lines joining the
boxes represent the switch from one treatment option to the alternative option(s). Horizontal lines join the number and the type of options to
which treatment change occurred in each step of switch. Boxes on the right of the figure report the percentage of patients involved in each step
of treatment switch.
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http://www.biomedcentral.com/1471-244X/13/98the patients accessed this service during the previous
90 days, for an average of 0.25 days/patient-month. Fur-
thermore, during the follow up period after enrolment,
the use of this resource increased in terms of both number
of accesses (up to 20) and number of patients involvedFigure 3 Persistence with antipsychotic drug treatment from enrolme
graph shows the probability of persistence (Y axis) during the therapy perio
grey curve for typical).(2.7%), hence in terms of total duration of staying. In
contrast, hospitalizations, mostly attributable to symptom
relapse, decreased on average, together with nurse home
visits. The specialist examinations did not show a well
defined trend during the follow-up.nt to endpoint or to patients’ withdrawal from the study. The
d (X axis) with the treatment drug class (black curve for atypical and
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As expected, the quota paid by most of the patients was
null, hence the amounts reported can be considered as cor-
responding to the amount paid by the NHS. Total direct
costs corresponded to an average of 408 €/patient-month
(Table 4) and were stable overall during the observational
period (F(2.3,1755) = 0.2, P = 0.842). In particular, 81.2% of
the patients cost less than 500 €/patient-month, 9.9% cost
between 500 and less than 2,000 €/patient-month, while
only 3.0% cost from 2,000 to 9,500 €/patient-month. The
cost driver was the pharmacological treatment, corre-
sponding to 30-36% of total medical costs. However, some
cost items varied differently during the observational
period: cost of treatment with antipsychotic drugs and for
accessing residential care units increased, while psycho-
therapy and hospital admissions decreased (Table 4).
The trend of direct costs found can be ascribed to two
main reasons: first – the decision to exclude patients liv-
ing in residential care units at enrolment caused lower
costs imputable to this reason, until the enrolment exam-
ination. Later, during the follow-up, the patients accessed
these units and stayed for up to 20 days/patient-month.
The daily cost of staying is high (on average 151 € per
day), which, multiplied by the long stays, contributed to a
considerable portion of the total costs. Second – 9.9% of
the patients were naïve at enrolment: until then the cost
for antipsychotic drug treatment of these patients was 28
€/patient-month (10 out of these 63 patients did not re-
ceive any treatment during the pre-enrolment period), as
compared with 108 €/patient-month spent for non naïve
patients, but reached 112.19 €/patient-month after one
year. On the other hand, the cost for hospital admissions
of naïve patients was 104 €/patient-month, reduced to
39.76 €/patient-month one year later; and that for psycho-
therapy was 45.70 €/patient-month, decreased to 8.21
€/patient-month one year later. However, total direct costs
were not significantly different between naïve and
non naïve patients, during the observational period
(F(2.3,1755) = 0.1, P = 0.964).
Indirect costs
Throughout the entire observational period, 62.2% of the
patients did not generate any loss in days of productivity,
for themselves or for their caregivers. Up to 5 days/
patient-month were lost by 28.7% of the patients, and
5–10 days/patient-month by 6.0%, while 10–31 days/
patient-month lost involved 3.2% of the patients.
The percentage of idle patients and of patients and
caregivers losing days of productivity decreased during
the follow up period. The mean number of days of prod-
uctivity lost also decreased among patients and care-
givers losing at least 1 day of productivity. As a result,
among the entire study sample, while an average of
3.5 days/patient-month was lost during the 90 daysbefore enrolment by patients and caregivers, this
amount decreased to less than 1 day/patient-month 1 year
later (Table 5).
Interestingly, among naïve patients, 7.4 days/patient-
month of productivity were lost by both the patients and
their caregivers before enrolment, while a reduction was
detected during follow-up, reaching 0.7 days/patient-
month. The other patients and their caregivers lost 3.1 -
days/patient-month before enrolment, with a reduction
to 0.7 days/patient-month during follow-up. The de-
creasing trend of productivity lost by all patients and
caregivers was statistically significant (F(1.8,1755) = 41.3,
P < 0.0001) and was significantly different between naïve
and non naïve patients (F(1.8,1755) = 7.8, P = 0.001). In
particular, in both the subgroups there was a significant
decrease in productivity lost between the enrolment
examination and the 3 follow up examinations (p < 0.001)
Outcomes during the follow-up
During the follow-up, the mean DAI-30 score remained
more or less stable in both naïve and non naïve patients,
although the naïve patients showed a slightly lower mean
level of attitude toward treatment (Table 6). Furthermore,
according to the clinicians, most of the patients did not
change their attitude or compliance toward treatment: in
particular, compared with the baseline, after one year
(follow-up examination 3) 70.5% did not change their
compliance, 14.4% improved it, while 15.2% worsened
their compliance with respect to the year before.
On the other hand, the patients’ clinical status mea-
sured by the physicians with the PANSS, the GAF and
the CGI-S scales, and patients’ HRQoL as reported by
the patients themselves, showed on average a significant
(P < 0.0001) improvement during follow-up (Table 6),
suggesting that the treatment strategy adopted in these
patients was beneficial to their health, according to both
physician’s and patient’s points of view.
In particular, the naïve patients had an average higher im-
provement than the non naïve patients, which was statisti-
cally significant in the SF-36 PCS and MCS scores (Table 6).
Among the non naïve patients, significant (p < 0.05) im-
provements were found between each pair of examinations,
in the CGI-S, GAF, PANSS and EQ-5D VAS mean scores.
However, the PCS mean score change was not significant
between enrolment and follow-up examination 1, and be-
tween follow-up examination 2 and examination 3, and
the MCS mean score change was not significant between
follow-up examinations 2 and 3. Finally, we found a sig-
nificant improvement with the EQ-5D utility score in all
pairs of examinations except between enrolment and
follow-up examination 1, and between follow up examin-
ation 1 and 2.
In the naïve group, there were significant improvements
(p < 0.05) in GAF and PANSS total mean score comparisons
Table 3 Consumption of health care services
Type of resource From −90 days to
enrolment (N = 637)
From enrolment to follow-up
examination1 (N = 614)
From follow-up
examination 1 to 2 (N = 603)
From follow-up
examination 2 to 3 (N = 587)
Psychotherapy
Any type
- Proportion of patients 24.3% 22.8% 20.9% 17.4%
- No. sessions/pat-month,
Mean (min-max)
1.7 (0.0-48.0) 1.6 (0.0-51.4) 1.6 (0.0-69.5) 1.3 (0–129.3)
Individual, group, familiar
psychotherapy
- Proportion of patients 15.9% 14.0% 12.6% 12.1%
- No. sessions/pat-month,
Mean (min- max)
0.7 (0.0-48.0) 0.5 (0.0-51.4) 0.6 (0.0-68.6) 0.5 (0.0-62.6)
Structured psychosocial
rehabilitation group
- Proportion of patients 6.8% 7.0% 6.6% 2.7%
- No. sessions/pat-month,
Mean (min-max)
0.6 (0.0-25.7) 0.5 (0.0-20.3) 0.5 (0.0-27.5) 0.4 (0.0-66.7)
Day center
- Proportion of patients 4.9% 5.9% 5.5% 4.8%
- No. sessions/pat-month,
Mean (min-max)
0.5 (0.0-24.0) 0.5 (0.0-22.9) 0.5 (0.0-23.5) 0.4 (0.0-24.1)
Residential care units
Proportion of patients 1.7% 2.0% 2.5% 2.7%
- No. any accesses 15 13 15 20
- No. accesses for symptom
relapse
6 6 8 6
- No. days/pat-month,
Mean (min-max)
0.25 (0–28.0) 0.32 (0–28.2) 0.53 (0–29.7) 0.6 (0.0-29.8)
Hospital admissions (full
day or day hospital)
- Proportion of patients for
any reason
11.9% 7.2% 6.6% 8.4%
- No. admissions/pat-
month, Mean (min-max)
0.05 (0.0-1.7) 0.03 (0.0-1.0) 0.03 (0.0-2.5) 0.02 (0.0-1.3)
- Proportion of patients for
symptom relapse
9.7% 4.7% 4.2% 6.5%
- No. admissions/pat-
month, Mean (min-max)
0.03 (0.0-1.0) 0.02 (0.0-1.0) 0.02 (0.0-0.9) 0.01 (0.0-0.7)
Nurse home visits
- Proportion of patients 7.4% 7.2% 5.1% 4.6%
- No. visits/pat-month,
Mean (min-max)
0.6 (0.0-60.0) 0.2 (0.0-64.3) 0.1 (0.0-7.8) 0.1 (0.0-8.3)
Specialist examinations*
- Proportion of patients 9.8% 11.7% 12.3% 16.2%
- No. examinations/pat-
month, Mean (min-max)
0.1 (0.0-23.3) 0.1 (0.0-4.5) 0.9 (0.0-3.6) 0.1 (0.0-11.9)
Diagnostic tests**
- Proportion of patients 29.0% 25.2% 24.2% 35.8%
- No. tests/pat-month,
Mean (min-max)
1.4 (0.0-40.0) 1.0 (0.0-23.0) 1.0 (0.0-18.0) 1.8 (0.0-27.7)
* More often psychiatrist, cardiologist, neurologist, gynaecologist or dietician. ** Blood tests and/or instrumental tests.
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Table 4 Direct medical costs
Variable description 90 days before
enrolment (N = 637)
From enrolment to
follow-up examination 1 (N = 614)
Between follow-up
examinations 1 & 2 (N = 603)
Between follow-up
examinations 2 & 3 (N = 587)
Mean
€/pat-month
% Mean €/pat-month % Mean €/pat-month % Mean €/pat-month %
Drug treatment 115.30 29.5 144.9 35.2 146.5 34.2 144.57 35.9
Antipsychotic drugs 100.70 25.8 127.9 31.1 129.0 30.2 127.83 31.7
Concomitant drugs 14.57 3.7 16.8 4.1 17.0 4.0 16.73 4.1
Psychotherapy 114.00 29.2 108.36 26.3 98.20 22.9 93.53 23.2
Hospitalizations, of
which
105.75 27.1 93.33 22.7 91.69 21.4 69.62 17.3
Full day admissions for
symptom relapse
85.51 21.9 42.76 10.4 38.87 9.1 34.14 8.5
Residential Care Units 37.22 9.5 49.11 11.9 80.60 18.8 85.06 21.1
Nurse home visits 9.21 2.4 10.02 2.4 5.46 1.3 4.67 1.2
Lab and instrumental
diagnostic tests
6.00 1.5 3.87 0.9 3.49 0.8 3.40 0.8
Specialist examinations 2.91 0.7 1.97 0.5 2.35 0.5 2.32 0.6
Total medical costs 390.39 100 411.61 100 428.27 100 403.17 100
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http://www.biomedcentral.com/1471-244X/13/98between at least two examinations. While significant im-
provements were observed between follow-up examinations
1 and 2 in the CGI-S score, between enrolment and follow-
up examination 3 in the EQ-5D VAS, PCS and MCS scores,
between enrolment and follow-up examination 2 in the EQ-
5D VAS and MCS scores, and between follow-up examin-
ation 1 and examination 3 in the EQ-5D VAS and PCS
scores. No significant improvements were found in the EQ-
5D utility score.
Discussion
The novelty of the present study is its ability to pro-
vide the currently available most complete picture on
the socio-economic burden and outcomes on youngTable 5 Loss of productivity among patients and their caregi
Variable description 90 days before
enrolment
(N = 637)
Frequency of idle patients 52.8%
Frequency of patients losing ≥1 day of productivity 23.3%
Frequency of caregivers losing ≥1 day of productivity 18.6%
No. days/patient-month of productivity loss (computed
among the whole study sample)
2.9 (0.0-30.0)
No. days/patient-month of productivity loss (computed
among patients loosing productivity)
12.6 (0.3-30.0)
No. days/caregiver-month of productivity loss
(computed among all caregivers in the study sample)
1.2 (0.0-30.0)
No. days/caregiver-month of productivity loss
(computed among caregivers loosing productivity)
6.3 (1.0-30.0)
No. days/patient-month of total productivity loss by
both patients and caregivers (computed among patients
study sample)
3.5 (0.0-60.0)
* values for days/person-month are mean values (min-max).patients with recent diagnosis of schizophrenia or
schizophreniform disorder, observed in a context of
real clinical practice.
The study showed how these patients received several
and complex treatments to manage their condition,
using the many options available in the healthcare sys-
tem. In particular, many antipsychotic drugs and con-
comitant therapies were used in different combinations.
As regards the antipsychotic drug treatment, we found a
higher persistence for the treatment with atypical anti-
psychotic drugs (more than 400 patient-days) than for
typical drugs (263 patient-days). In this study we saw
also how clinical and perceived health can change (im-
prove) in nearly one year, according to the treatmentvers*
From enrolment to
follow-up examination 1
(N = 614)
From follow-up
examination 1 to 2
(N = 603)
From follow-up
examination 2 to 3
(N = 587)
51.3% 50.8% 49.3%
8.5% 7.3% 9.4%
8.7% 11.0% 11.0%
1.0 (0.0-30.0) 0.6 (0.0-30.0) 0.6 (0.0-30.0)
12.0 (0.3-30.0) 8.4 (0.3-30.0) 6.2 (0.4-30.0)
0.2 (0.0-7.5) 0.5 (0.0-28.1) 0.2 (0–5.4)
2.8 (0.3-7.5) 4.1 (0.6-28.1) 1.5 (0.4-30.0)
1.1 (0.0-31.7) 0.8 (0.0-33.7) 0.7 (0.0-30.0)
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http://www.biomedcentral.com/1471-244X/13/98strategies adopted. The full sample showed an overall
improved trend in both clinical and perceived health
(i.e., HRQoL): however, this improvement was on ave-
rage higher among the naïve patients, i.e., those patients
that were seen at the participating centres and started to
receive health care starting from their enrolment in the
study. Not only did clinical outcomes and HRQoL im-
prove on average, but also the patients’ productivity.
Furthermore, while no significantly different overall dir-
ect costs trends were found between naïve (i.e., patients
that had started or changed antipsychotic treatment re-
cently) and non naïve patients, naïve patients showed
generally a significant mean higher improvement of clin-
ical outcomes, HRQoL and indirect costs, compared to
the others. However, the study sample was probably not
suitable to obtain reliable results from these compari-
sons. Our results have a trend similar to that found in
other studies, where treatment is associated with im-
provement in HRQoL [17,18] and clinical outcomes.
[19-21]. A similar trend was found also by Strakowsi
et al.[24], who showed that among patients with newly
onset schizophrenic disorder, treatment is associated
with improvements in most HRQoL domains, measured
with the SF-36 instrument. Other studies show that out-
comes in patients with a first-episode psychosis may be
improved by an early intervention treatment and reduc-
tion of the untreated period [22,23,25-27] but long term
effects are still not clear [26-28].
In our study sample, a quarter of medical costs are at-
tributable to antipsychotic drug treatment, followed by
costs for psychotherapy and for hospital admissions:
these results are different from those obtained in previ-
ous research, where it has been shown that the highest
proportion of direct costs is attributable to in-patient
care, while drug treatment generates lower costs
[7-10,16]. However, it must be noted that the data avail-
able in the literature refer to different populations from
different countries, where different treatment modalities
could be applied, or different unit costs are applicable,
or which include older patients than those involved in
our study [6-11,13-15,51,52]. In our study, medical costs
during the follow up period remained stable overall.
However, while some cost items increased (antipsychotic
drug treatment, admission to health care units), others
decreased (mainly hospital costs for symptom relapses),
which could have depended also on the patients’ inclu-
sion criteria at enrolment. Previous studies have demon-
strated that loss of productivity is the main component
of overall cost of schizophrenia [6-10,13-15,51,52]. Our
results confirm the high productivity loss among pa-
tients and their family caregivers, measured in terms of
frequency of idle patients and in terms of days lost from
productivity. However, we also observed a reduction of
productivity loss during the follow up. This point is ofgreat interest from the societal point of view, since
schizophrenia is associated with poverty and homeless-
ness, thus representing a significant amount of resource
costs to deal with these problems. The National Institute
for Health and Clinical Excellence (NICE) has recently
recommended taking into account wider societal costs, in-
cluding productivity losses of people with schizophrenia
and of their family caregivers’, when cost-effectiveness of
treatment is assessed [52]. It must be noted that it is not
easy to also include loss of productivity in the computation
of costs [9], and this loss often remains excluded from cal-
culations: for instance, Serretti and co-workers highlighted
its importance, but did not include this parameter in their
Italian simulation of the socio-economic burden of schizo-
phrenia [53]. Palazzolo et al. [54] pointed out that the com-
bination of early diagnosis and the use of atypical
medications would change the face of schizophrenia,
allowing many patients to start working again. Our find-
ings suggest that appropriate therapy reduces loss of prod-
uctivity in a relatively short time period and that it may
also promote an increment of the working/job inclusion of
schizophrenia patients, improving in turn their social
networks.
The treatment pattern observed in this study, which
required several switches between drugs, demonstrates
how treating patients with schizophrenia requires the
availability of a wide and complex armamentarium of
products (e.g., drugs) and services (e.g., psychosocial
treatment, psychotherapy, etc.), likely involving different
interacting factors, such as clinical severity, patient com-
pliance, service accessibility [55]. In this regard, the most
recent NICE guidelines [52] report that choosing the
most appropriate drug and formulation according to
each patient’s needs and characteristics might be more
important than only taking into account the main recog-
nized properties of the different classes of drugs. In this
way, NICE acknowledges the importance of a personal-
ized treatment and highlights the importance of high
levels of adherence to antipsychotic treatment to reduce
the risk of relapse and further hospitalization costs.
Our study has some potential limitations: first, there
was no control group in the present study, hence, we
could not verify if the trends estimated with the different
measures completed by the patients or the clinicians
might actually represent a practice effect, i.e., an increase
in the test scores from one administration to the next
without any intervention. However, in a recent study
aimed at investigating practice effects on a battery of
scales, this was not found on the PANSS and on a visual
analogue scale analysing the HRQoL [56]. Second, al-
though we could preliminarily estimate the possible in-
cremental benefit attributable to the treatment applied
on naïve patients, our sample size was too small to draw
reliable results and conclusions. However, with regard to
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http://www.biomedcentral.com/1471-244X/13/98these two limits, this study was not designed for making
comparisons between different patients, but rather to
observe treatment strategies adopted in clinical practice
and related consequences on patients’ health and costs
to society. Third, the study may suffer from a selection
bias, as patients who participated may be more likely to
comply with medication than the overall target popula-
tion. Fourth, our results on the higher persistence for
atypical versus typical drugs classes could partially de-
pend on the higher proportion of patients using atypical
drugs, hence on a possible bias attributable to that these
patients more probably switched to another atypical
drug, which could not have been detected because we
limited the attention on classes of drugs rather than on
molecules. Nevertheless, the difference of persistence be-
tween the two classes of drugs appeared relevant. The
approach we used to measure persistence in this study is
not commonly applied and not comparable to those
adopted in other studies conducted in this sector, where
the observation was restricted to a limited number of
drugs used (e.g., one out of 4 drugs in the CATIE ran-
domized controlled study [19], one out of 7 drugs in the
naturalistic study by Guo et al. [57]). However, because
our study aimed at obtaining a real-world picture of our
target population, we did not impose any criteria in re-
gard to the treatment followed during the observational
period. As a consequence, we enrolled patients that were
using different combinations of many different anti-
psychotic drugs (18 in total), obtaining information that
can actually be considered new for the community. Al-
though not common, the approach of measuring persist-
ence on classes of drugs can be useful to show the
natural complexity of a treatment pattern, similarly to
other areas, e.g., hypertension [58]. However, because we
did not observe persistence between molecules, or even
dosages, within the same class of drugs, we obtained re-
sults that should be considered conservative. Neverthe-
less, our results already show how complex is the
antipsychotic treatment even considering only classes of
drugs, and suggest a much higher complexity that can
be relevant for the treatment decisions and related con-
sequences. Fifth, although we observed interesting and
promising trends in a prospective1-year observation, this
time horizon is however too short to know the long
term consequences related to the strategy adopted in
schizophrenic patients. Finally, some criticisms could
arise with regard to the approach used to estimate direct
and indirect costs. Regarding direct costs, we did not es-
timate non-medical costs (e.g. costs of transportation,
housekeeping): we chose this approach because we con-
sidered the informative gain attributable to these costs,
which we expected not to be relevant if compared to the
other costs, not enough to justify the additional cognitive
burden that would be caused by requesting more detailsfrom the patients. Indirect costs were not monetized: we
chose this approach because of the high risk of underesti-
mating indirect costs in a population where many patients
are still students, many others are idle or have an unpaid
job. We consider it more accurate and informative to de-
scribe and provide a picture of the study sample according
to the patient’s educational and working status and to esti-
mate the number of days that they and their caregivers
miss work, school, or the possibility to do their usual
activities.
As in the other studies focusing on costs e.g., [10,59],
our estimates are not totally applicable to other health
care systems, because of the unavoidable country specifi-
city of some data (e.g., unit costs) and methodologies
used to conduct the study and perform the analyses. To
expand applicability of our results, among the results we
specify the mean consumption of specific categories of
resources, which could be multiplied by different unit
costs that are applicable in other health care systems. In
any case, by keeping in mind the possible differences
and adjustments to be made between the different
healthcare sectors, these estimates remain valid to allow
the community to understand the type and amount of
the implications that are related to the management of
subjects with the condition under study.
Conclusion
In conclusion, this study provides a real-world complete
picture of persistence, compliance, healthcare costs, loss
of productivity, health related quality of life and clinical
outcomes in young schizophrenia patients treated with
the several options available. Our results suggest how
tailoring the treatment strategy according to the com-
plex and specific patient needs is necessary to gain bene-
fits and to make allocation of resources more efficient.
Finally, this study can also provide information on the
most relevant items to be considered when conducting
cost-effectiveness studies comparing specific alternatives
for the treatment of target patients.
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